Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regulus Therapeutics

8.16
0.0000
Volume:- -
Turnover:75.91M
Market Cap:564.95M
PE:-11.28
High:8.16
Open:8.16
Low:8.16
Close:8.16
Loading ...

BRIEF-Regulus Therapeutics Enters Into Agreement To Be Acquired By Novartis AG

Reuters
·
30 Apr

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

GlobeNewswire
·
30 Apr

Regulus Therapeutics Inc - Deal Valued up to $1.7 Billion With Contingent Value Right

THOMSON REUTERS
·
30 Apr

Regulus Therapeutics Enters Into Agreement to Be Acquired by Novartis Ag

THOMSON REUTERS
·
30 Apr

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

PR Newswire
·
30 Apr

Should You Buy Regulus (RGLS) After Golden Cross?

Zacks
·
24 Apr

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

PR Newswire
·
02 Apr

Oppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)

TIPRANKS
·
28 Mar

Regulus Therapeutics Inc : Wells Fargo Raises to Overweight From Equal Weight; Raises Target Price to $6 From $3

THOMSON REUTERS
·
28 Mar

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
28 Mar

Regulus Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo

Dow Jones
·
28 Mar

Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise

MT Newswires Live
·
28 Mar

Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease

MT Newswires Live
·
28 Mar

BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease

Reuters
·
27 Mar

Regulus Therapeutics Inc -Positive Topline Data From Fourth Cohort of Patients

THOMSON REUTERS
·
27 Mar

Regulus Therapeutics Inc -on Track for Initiation of Phase 3 Single Pivotal Trial in Q3 2025

THOMSON REUTERS
·
27 Mar

Regulus Therapeutics-Patients Receiving 300 Mg Farabursen Demonstrated Mean Halting of Height-Adjusted Total Kidney Volume Growth Over 4 Months

THOMSON REUTERS
·
27 Mar

Regulus Therapeutics Announces Successful Completion of Its Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Farabursen (Rgls8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (Adpkd)

THOMSON REUTERS
·
27 Mar

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PR Newswire
·
27 Mar

Regulus Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
17 Mar